Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC

NCT06024226 | Not Yet Recruiting

• 1 other identifier: CHUBX 2023/35
• Study Type: observational
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to cellular and soluble immunosuppressive mechanisms. MDSC are one of the most important immunosuppressive cells, that also harbour non immunologic functions, favouring cancer invasion. These non immunologic functions of MDSC in lung cancer will be better characterized. Indeed, cellular mechanisms will be analysed by in vitro studies, assessing the effect of immunosuppressive cells, provided by fresh tumor samples, on phenotype and functions of lung cancer cell lines. The aim of this study is to better characterize immunosuppressive landscape of NSCLC and mechanisms involved in their protumor functions.

Conditions

Lung Neoplasms; Myeloid-Derived Suppressor Cells; Immunosuppression

Keywords

Lung cancer; Immunosuppression; Immuno-oncology; Antitumor immune escape; Invasion

Outcome Measures

Primary Outcomes (1)

• Comparative analysis of the modifications of phenotype and functions of lung cancer cell lines when exposed to MDSC extracted from patient tumor tissue

  Functional in vitro studies of the effect of MDSC extracted from resected NSCLC prospectively collected on phenotype and function of lung cancer cell lines

  At the time of surgery only, when fresh tumor is resected

Study Arms (1)

Patients with lung carcinoma surgically treated by surgery only

Procedure: Tumor samples

Interventions

Tumor samples PROCEDURE

Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery

Patients with lung carcinoma surgically treated by surgery only

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with lung carcinoma surgically treated by surgery only

You may qualify if:

• consecutive patients
• lung carcinoma surgically treated by surgery only

You may not qualify if:

• patient receiving chemotherapy, radiotherapy or immunotherapy in the neoadjuvant setting (all objectives)
• patient with concomitant or previous cancer (in the 2 years)

Sponsors & Collaborators

• University Hospital, Bordeaux: lead

Study Sites (1)

CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale

Bordeaux, 33000, France

Location

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Charlotte DOMBLIDES

CONTACT

charlotte.domblides@chu-bordeaux.fr

Matthieu THUMEREL

CONTACT

matthieu.thumerel@chu-bordeaux.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 28, 2023
• First Posted: September 6, 2023
• Study Start: December 1, 2025
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: July 30, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)